



www.MedChemExpress.com

Inhibitors, Screening Libraries, Proteins









Arp2/3 Complex

Actin-related protein 2/3 complex

The Arp2/3 complex is originally identified in *Acanthamoeba* and consists of seven proteins (actin-related proteins; Arp2 and Arp3, and Arp2/3 complex subunits; ARPC1-5) that are conserved in all eukaryotes, with the exception of some algae, microsporidia and protists. The complex plays an essential role in a wide variety of cellular processes including lamellipodia-mediated cell migration, endocytosis and phagocytosis, by virtue of its ability to generate branched actin filament networks

Activation of Arp2/3 requires interaction with actin nucleation-promoting factors (NPFs). Regulation of Arp2/3 activity is achieved by endogenous inhibitory proteins through direct binding to Arp2/3 and competition with NPFs or by binding to Arp2/3-induced actin filaments and disassembly of branched actin networks. Arp2/3 inhibition has recently garnered more attention as it has been associated with attenuation of cancer progression, neurotoxic effects during drug abuse, and pathogen invasion of host cells


Arp2/3 Complex Inhibitors, Activators & Chemicals

<p>187-1, N-WASP inhibitor</p> <p style="text-align: right;">Cat. No.: HY-P1045</p> <p>187-1, N-WASP inhibitor, a 14-aa cyclic peptide, is an allosteric neural Wiskott-Aldrich syndrome protein (N-WASP) inhibitor. 187-1, N-WASP inhibitor potently inhibits actin assembly induced by phosphatidylinositol 4,5-bisphosphate (PIP2) with an IC_{50} of 2 μM.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p> <p style="text-align: right;"><small>Cyclic-[6-Phe]-[6-Pro]-[6-Phe]-F-[6-Pro]-Q[2]</small></p>	<p>187-1, N-WASP inhibitor TFA</p> <p style="text-align: right;">Cat. No.: HY-P1045A</p> <p>187-1, N-WASP inhibitor TFA, a 14-aa cyclic peptide, is an allosteric neural Wiskott-Aldrich syndrome protein (N-WASP) inhibitor.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p> <p style="text-align: right;"><small>Cyclic[6-(6-Phe)-[6-Pro]-[6-Phe]-F-[6-Pro]-Q[2] (TFA salt)</small></p>
<p>Benproperine phosphate</p> <p style="text-align: right;">Cat. No.: HY-114657A</p> <p>Benproperine phosphate is an orally active, potent actin-related protein 2/3 complex subunit 2 (ARPC2) inhibitor. Benproperine phosphate attenuates the actin polymerization rate of action polymerization nucleation by impairing Arp2/3 function.</p> <p>Purity: 99.23% Clinical Data: Launched Size: 10 mM \times 1 mL, 100 mg</p> <p style="text-align: right;"></p>	<p>CK-636 (CK-0944636)</p> <p style="text-align: right;">Cat. No.: HY-15892</p> <p>CK-636 is a cell permeable inhibitor of Arp2/3 complex, that could inhibit actin polymerization, with IC_{50} values of 4 μM, 24 μM and 32 μM for human, fission yeast and bovine, respectively.</p> <p>Purity: 98.43% Clinical Data: No Development Reported Size: 10 mM \times 1 mL, 10 mg, 50 mg, 100 mg</p> <p style="text-align: right;"></p>
<p>CK-666</p> <p style="text-align: right;">Cat. No.: HY-16926</p> <p>CK-666 is a cell-permeable actin-related protein Arp2/3 complex inhibitor (IC_{50}=12 μM). CK-666 binds to Arp2/3 complex, stabilizes the inactive state of the complex, blocking movement of the Arp2 and Arp3 subunits into the activated filament-like (short pitch) conformation.</p> <p>Purity: 99.79% Clinical Data: No Development Reported Size: 10 mM \times 1 mL, 5 mg, 10 mg, 50 mg</p> <p style="text-align: right;"></p>	<p>CK-869</p> <p style="text-align: right;">Cat. No.: HY-16927</p> <p>CK-869 is an Actin-Related Protein 2/3 (ARP2/3) complex inhibitor, with an IC_{50} of 7 μM.</p> <p>Purity: 99.74% Clinical Data: No Development Reported Size: 10 mM \times 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p> <p style="text-align: right;"></p>
<p>Cytochalasin B (Phomin)</p> <p style="text-align: right;">Cat. No.: HY-16928</p> <p>Cytochalasin B is a cell-permeable mycotoxin binding to the barbed end of actin filaments, disrupting the formation of actin polymers, with K_d value of 1.4-2.2 nM for F-actin.</p> <p>Purity: 99.84% Clinical Data: No Development Reported Size: 10 mM \times 1 mL, 1 mg, 5 mg, 10 mg</p> <p style="text-align: right;"></p>	<p>Cytochalasin D (Zygosporin A; NSC 209835)</p> <p style="text-align: right;">Cat. No.: HY-N6682</p> <p>Cytochalasin D (Zygosporin A; NSC 209835) is a potent and cell-permeable inhibitor of actin polymerization derived from fungus, inhibits the G-actin-cofilin interaction by binding to G-actin.</p> <p>Purity: 99.75% Clinical Data: No Development Reported Size: 10 mM \times 1 mL, 1 mg, 5 mg, 10 mg</p> <p style="text-align: right;"></p>
<p>Dihydrocytochalasin B</p> <p style="text-align: right;">Cat. No.: HY-N6701</p> <p>Dihydrocytochalasin B (H2CB) is a Cytokinesis inhibitor and changes the morphology of the cells, similar to that of cytochalasin B; does not inhibit glucose transport.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p> <p style="text-align: right;"></p>	<p>Jasplakinolide</p> <p style="text-align: right;">Cat. No.: HY-P0027</p> <p>Jasplakinolide is a potent actin polymerization inducer and stabilizes pre-existing actin filaments. Jasplakinolide binds to F-actin competitively with phalloidin with a K_d of 15 nM.</p> <p>Purity: \geq98.0% Clinical Data: No Development Reported Size: 100 μg</p> <p style="text-align: right;"></p>

Latrunculin A (LAT-A)

Cat. No.: HY-16929

Latrunculin A (LAT-A) is a toxin isolated from the red sea sponge *Latrunculia magnifica*, binds to actin monomers, inhibits polymerization of actin, with K_d s of 0.1, 0.4, 4.7 μ M and 0.19 μ M for ATP-actin, ADP-Pi-actin, ADP-actin and G-actin, respectively.



Purity: \geq 97.0%
Clinical Data: No Development Reported
Size: 100 μ g (237.2 μ M * 1 mL in Ethanol)

Phalloidin-TRITC

Cat. No.: HY-P2270

Phalloidin-TRITC is a TRITC labeled, red fluorescence probe for F-actin. Phalloidin, bound to actin filaments, reacts covalently with amino acids Glu-I17, Met-I19, and Met355, which are very close to the nucleotide binding site.


A-68-Thr-C-(His)-AW-(Trp) (Covalent bridge Cys3-Tyr6)

Purity: $>$ 98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SMIFH2

Cat. No.: HY-16931

SMIFH2 is a **formin** specific inhibitor. SMIFH2 inhibits actin polymerization by Formins and affects the actin cytoskeleton.




Purity: 98.22%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

Wiskostatin

Cat. No.: HY-12534

Wiskostatin is a potent and selective inhibitor of neuronal Wiskott-Aldrich syndrome protein (N-WASP)-mediated actin polymerization. Wiskostatin causes a rapid, profound, and irreversible decrease in cellular ATP levels.



Purity: $>$ 98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg